HOME >> BIOLOGY >> NEWS
Amgen's decision to block reinstatement of GDNF is faulted by a leading Parkinson's advocacy group

effects of Parkinson's disease. Since the trial was halted last summer, many of these people, supported by organizations and thousands of well-wishers from around the Parkinson's community, have pleaded with Amgen to reinstate those subjects who wish to continue with the treatment and are willing to be carefully followed to generate ongoing data. We understand and fully accept that such reinstatement of treatment should take place only with appropriate waivers that would hold the company harmless in event of any complications, whether foreseen or unforeseen, and with the approval of the relevant Institutional Review Boards."

"The safety issues of neutralizing antibodies (found in some of the human subjects) and of cerebellar degeneration involving high-dosage GDNF (in some non-human primate subjects) need to be investigated and understood. If subjects are willing to offer themselves for continuing GDNF infusion with all of these safety concerns fully explained and understood by the subjects, then the Parkinson community science as well as patients can gain much new information related to the safety of GDNF infusions."

"In summary, the decision is a mistake because it denies the patients and their doctors the opportunity to continue with a potentially useful, albeit yet unproven, treatment, and it denies us all the opportunity to gather more scientific data about the long-term effects of GDNF. We hope very much that this company, which has long held a position of high respect in the business and health communities, will consider reversing its decision, and soon. In the meantime, the coalition of patient-voluntary groups which besides PDF includes the Parkinson's Action Network and the Parkinson's Pipeline Project -- will continue fighting for patients' interests as long as it takes."


'"/>

Contact: Christiana Evers
cevers@pdf.org
Parkinson's Disease Foundation
11-Feb-2005


Page: 1 2

Related biology news :

1. A nurse makes the decision on who will live
2. Cells use noise to make cell-fate decisions
3. Group decisions: From compromise to leadership in pigeon homing
4. AIUM supports FDA decision to deny over-the-counter use of handheld doppler fetoscopes
5. Titans of biodiversity science call for united, authoritative voice to inform decision-makers
6. Dover intelligent design decision to be topic of national forum
7. Honeybee decision-making ability rivals any department committee
8. Even at small scales, the big decisions are made at the water cooler
9. Amid growing public concerns, bioscience firms begin formalizing ethical decision-making practices
10. Ethical decision-making at bioscience companies
11. Dover decision is good for long-term economic and scientific strength

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/21/2016)... 2016 NuData Security announced today that Randy ... principal product architect and that Jon Cunningham ... development. Both will report directly to Christopher ... reflect NuData,s strategic growth in its product and ... demand and customer focus values. ...
(Date:6/16/2016)... FRANCISCO , June 16, 2016 ... size is expected to reach USD 1.83 ... by Grand View Research, Inc. Technological proliferation and ... banking applications are expected to drive the market ... ) , The development of advanced ...
(Date:6/9/2016)... , June 9, 2016  Perkotek an innovation leader in attendance control systems is ... log work hours, for employers to make sure the right employees are actually signing ... http://photos.prnewswire.com/prnh/20160609/377486LOGO ... ... ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... June 23, 2016  Blueprint Bio, a company dedicated ... the medical community, has closed its Series A funding ... . "We have received a commitment from ... we need to meet our current goals," stated ... the runway to complete validation on the current projects ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... exhibiting at the Pennsylvania Convention Center and will showcase its product’s latest features ... will also be presenting a scientific poster on Disrupting Clinical Trials in The ...
(Date:6/23/2016)... -- Amgen (NASDAQ: AMGN ) today announced a ... sciences incubator to accelerate the development of new therapies ... QB3@953 was created to help high-potential life science and ... stage organizations - access to laboratory infrastructure. ... "Amgen Golden Ticket" awards, providing each winner with one ...
(Date:6/22/2016)... Research and Markets has announced the addition of the ... The global biomarkers market ... 2013. The market is expected to grow at a five-year compound ... from $50.6 billion in 2015 to $96.6 billion in 2020. ... (2015 to 2020) are discussed. As well, new products approved in ...
Breaking Biology Technology:
Cached News: